Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 579-584

  Fontanini, G ^a   Campani, D ^a   Roncella, M ^a   Cecchetti, D ^a   Calvo, S ^a   Toniolo, A ^b   Basolo, F ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Breast cancer; Cytokines; ER; IL 6; Ki67; p53; PgR

Indexed keywords

ESTROGEN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GRADING; CANCER GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR VOLUME;

EID: 0032908708     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690394     Document Type: Article

References (33)

1. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M. Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankestein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L and Forni G (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL) -2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54: 6022-6026
2. Basolo F, Conaldi PG, Fiore L, Calvo S and Toniolo A (1993a) Normal breast epithelial cells produce interleukin 6 and 8 together with tumor-necrosis factor: defective IL-6 expression in mammary carcinoma. Int J Cancer 55: 1-5
3. Basolo F, Calvo S, Fiore L, Conaldi PG, Falcone V and Toniolo A (1993b) Growth-stimulating activity of interleukin 6 (IL-6) on human mammary epithelial cells transacted with the int-2 gene. Cancer Res 53: 2957-2960
4. Basolo F, Fiore L, Calvo S, Falcone V, Conaldi PG, Fontanini G, Caligo AM, Merlo G, Gluzman Y and Toniolo A (1996a) Defective IL-6 expression and responsiveness in human mammary cells transformed by an adeno-5/sv40 hybrid virus. Br J. Cancer 73: 1156-1361
5. Basolo F, Fiore L, Fontanini G, Conaldi PG, Calvo S, Falcone V and Toniolo A (1996b) Expression of interleukin 6 (IL-6) and response to it in human mammary tumours. Cancer Res 56: 3118-3122
6. Basolo F, Fiore L. Pollina L, Fontanini G, Conaldi PG and Toniolo A (1998) Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies. Clin Cancer Res 4: 381-387
7. Campani D, De Negri F, Martini L, Giani C. Squartini F and Sarnelli R (1991) Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers, 6: 144-150
8. Castelli C, Sensi M, Lupetti R, Mortarini R, Panceri P, Anichini A and Parmiani G (1994) Expression of interleukin 1α, interleukin 6, and tumour necrosis factor α genes in human melanoma clones is associated with that of mutated N-ras oncogene. Cancer Res 54: 4785-4790
9. Chen I, Mory Y, Zilberstein A and Revel M (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β. Proc Natl Acad Sci USA, 85: 8037-8041
10. Chin JJ, Sgagias MK and Cowan KH (1996) Interteukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 2: 215-221
11. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D and Rouesse J (1987) The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients, uniformly treated at the Institut Gustave Roussy. J Clin Oncol 5:1378-1386
12. Danforth DN and Sagias MK (1993) Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 53: 1538-1545
13. Gandour-Edwards R, Kapadia SB, Gumerlock PH and Barnes AL (1995a) Immunolocalization of interleukin-6 in salivary gland tumors. Hum Pathol 26: 501-503
14. Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ and Barnes L (1995b) Biological markers of invasive pituitary adenomas involving the sphenoid sinus. Modl Pathol 8: 160-164
15. Garver RI, Radford DM, Donis-Keller H, Wick MR and Milner PG (1994) Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74: 1584-1590
16. Hirano T (1994) Interleukin-6. In The Cytokine Handbook, Thomson A (ed), pp. 145-168. Academic Press: London
17. Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TWJ and Home CHW (1996) p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29-36
18. Hug H (1997) Fas-mediated apoptosis in tumor formation and defense. Biol Chem 378:1405-1412
19. Keane MM, Ettemberg SA, Lowrey GA. Russel EK and Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791-4798
20. Lu C and Kerbel RS (1993) Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288
21. Margulies L and Schgal B (1993) Modulation of the Interleukin-6 promoter (IL-6) and transcription factor C/EBPb /NF-IL-6) activity by p53 species. J Biol Chem 268: 15096-15100
22. Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FMB and Zentella A (1992) Transforming growth factor-β. In Tumor Suppressor Genes, the Cell Cycle and Cancer, Levine AJ (ed), pp. 81-103. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY
23. Michiel DF and Oppenheim JJ (1992) Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 3: 3-15
24. Porter JK and Lippman ME (1994) Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am, 8: 73-100
25. Ray A and Prefontaine KE (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91: 752-756
26. Reed MJ, Coldham NG, Patel SR, Ghilcchick MW and James VHT (1992) Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Endocrinol 132: R5-R8
27. Rosen PP and Oberman HA (1993) Tumors of the mammary gland. In Atlas of Tumor Pathology, Rosai J (ed), pp. 7-10. Armed Forces Institute of Pathology: Washington, DC
28. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C and Mancuso S (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71: 354-356
29. Silberstain GB, Flanders KC, Roberts AB and Daniel CW (1992) Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-β 1. Dev Biol 152: 354-362
30. Silvani A, Ferrari G, Paonessa G, Toniatli C, Parmiani G and Colombo MP (1995) Down-regulation of interleukin 6 receptor α chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Cancer Res 55: 2200-2205
31. Stein B and Yang M (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPb. Mol and Cellular Biol 4971-4979
32. Stenmark-Askmalm M, Stal O, Olsen K and Nordenskjold B (1995) p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group. Br J Cancer 72: 715-719
33. von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH and Moller P (1998) Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58: 526-534